A novel vaccine adjuvant based on a supramolecular hydrogel of a D-tetra-peptide is reported. Antigens can be easily incorporated into the hydrogel by a vortex or by gently shaking before injection. The vaccines can stimulate strong CD8+ T-cell responses, which significantly inhibits tumor growth. This novel adjuvant is expected to enable a wide range of sub-unit vaccines and help the production of antibodies.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: